Additional file 1: Table S1. Patient and subgroup characteristics.

|  |  |  |
| --- | --- | --- |
| GROUP I (116 patients, 131 samples) |  |  |
|  Sex |  |  |
|  Male | *Patients* | 90 |
|  Female | *Patients* | 26 |
|  Female/male | *Ratio* | 1:1.41 |
|  Age at the time of LP |  |  |
|  Median | *Years* | 65 |
|  Range | *Years* | 19-85 |
|  Ethnic origin |  |  |
|  Caucasian | *%* | 88 |
|  African | *%* | 5 |
|  Turkish/Middle-Eastern | *%* | 4 |
|  Asian | *%* | 3 |
|  Manifestations at the time of LP (more than one per patient possible): |  |  |
|  Encephalopathy/disturbed consciousness | *Samples* | 63 |
|  Seizures/epilepsy-like EEG changes | *Samples* | 27 |
|  Cerebral ischemia/bleeding | *Samples* | 14 |
|  Myelitis | *Samples* | 3 |
|  Other CNS manifestations | *Samples* | 25 |
|  PNP (incl. GBS) | *Samples* | 22 |
|  Cranial nerves | *Samples* | 10 |
|  Headache | *Samples* | 13 |
|  Clinical subgroups (based on manifestations at the time of LP) |  |  |
|  'B/SC' subgroup | *Samples* | 108 |
|  <=14 days between neurological onset and LP | *%* | 75 |
|  'PN/CN/H only' subgroup | *Samples* | 22 |
|  <=14 days between neurological onset and LP | *%* | 89 |
|  Immunotherapy-related subgroups |  |  |
|  Untreated at the time of LP | *Samples* | 89 |
|  Treated at the time of LP | *Samples* | 29 |
|  Severity of the neurological symptoms, as per judgment of the  |  |  |
|  treating centers, at the time of LP |  |  |
|  'Mild' | *%* | 17.4 |
|  'Non-mild' (i.e., 'moderate' or 'severe') | *%* | 82.6 |
|  |  |  |
| GROUP II (11 patients, 19 samples) |  |  |
|  Sex |  |  |
|  Male | *Patients* | 5 |
|  Female | *Patients* | 6 |
|  Female/male | *Ratio* | 1:0.8 |
|  Age at the time of LP |  |  |
|  Median | *Years* | 54 |
|  Range | *Years* | 29-76 |
|  Ethnic origin |  |  |
|  Caucasian | *%* | 82 |
|  African | *%* | 0 |
|  Turkish/Middle-Eastern | *%* | 9 |
|  Asian | *%* | 9 |

Abbreviations: *B/SC* brain/spinal cord, *PN/CN/H* peripheral nerve/cranial nerve/headache only, *CNS* central nervous system, *EEG* electroencephalography, *GBS* Guillain‒Barre syndrome, *LP* lumbar puncture, *PNP* peripheral neuropathy.